CRISPR Therapeutics, a pioneer in gene therapy, faces challenges despite its first FDA-approved CRISPR-based therapy, Casgevy. With shares down 46% from their peak and minimal revenue reported, the company must navigate intense competition and financial losses while aiming for future growth. Investors are advised to proceed with caution until sales momentum is evident.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
